Product name: Eriodictyol 7-O-glucoside
Synonym name:
Catalogue No.: BP2164
Cas No.: 38965-51-4
Formula: C21H22O11
Mol Weight: 450.396
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of Eriodictyol 7-O-glucoside
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
219.0900
-1.5000
-2.0000
Low
No
No
No
No
No
No
Eriodictyol 7-O-glucoside (Eriodictyol 7-O-β-D-glucoside, hereinafter referred to as "Eriodictyol-7-O-glucoside") is a natural flavonoid compound that has attracted attention for its significant antioxidant and neuroprotective effects. As an activator of the Nrf2 (nuclear factor 2-related factor 2) pathway, sanchlorol-7-O-glucoside can regulate intracellular redox balance and induce antioxidant enzyme expression, providing potential therapeutic strategies for various oxidative stress-related diseases. In recent years, with deeper understanding of the role of oxidative stress in disease onset, research on sacrofol-7-O-glucoside in ischemic stroke, neurodegenerative diseases, and immune-related diseases has increased, demonstrating good pharmacological activity and safety profile. This paper will systematically review the chemical structure, sources, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of satrinal chlorphenol-7-O-glucoside, aiming to provide scientific basis for further development and application.
Acetifol-7-O-glucoside belongs to the flavanoid glycoside class of flavonoids, with a molecular formula of C21H22O11 and a molecular weight of 466.39. Its structure consists of a flavanone backbone of Eriodictyol connected to a glucose molecule formed by a β-D-glucosidic bond formed at the 7-position hydroxyl group. This structure imparts excellent water solubility (LogP about -1.5) and high polarity (TPSA of 219.09 Ų), with a hydrogen bond acceptor count of 11, demonstrating strong hydrophilicity.
From a physicochemical property perspective, sancafurol-7-O-glucoside has good water solubility, facilitating absorption and distribution in the body, but its blood-brain barrier penetration ability is relatively low, suggesting that its direct effect in the central nervous system may be limited and requires specific drug delivery systems or metabolic transformation to achieve neuroprotective functions. Additionally, in vitro and in vivo safety evaluations showed no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and Ames-related mutagenicity tests were negative, indicating a solid safety foundation.
Sacred Herbal-7-O-glucoside is mainly found in various traditional medicinal plants, especially those belonging to the Lamiaceae and Rutaceae families, such as Eriodictyon spp. and citrus plants. Its content is greatly influenced by plant species, growing environment, and harvest time.
The extraction method usually uses water or methanol as solvent, and crude extracts are obtained through ultrasound-assisted extraction or reflux extraction. Purification was then performed using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), ultimately yielding high-purity santhalol-7-O-glucoside. In recent years, the application of supercritical fluid extraction and membrane separation technologies has also improved extraction efficiency and purity, reducing solvent residues and environmental pollution.
Trichlorol-7-O-glucoside exhibits significant free radical scavenging ability, especially strong scavenging of hydroxyl radicals and superoxide anions, with IC50s of 0.28 mM and 0.30 mM, respectively. This antioxidant activity is mainly attributed to the polyhydroxyl structure of its flavonoid framework and the stabilizing action of glucosides, which can effectively trap free radicals and reduce cellular damage caused by oxidative stress.
In the in vitro oxygen-glucose deprivation (OGD)-induced neuronal oxidative damage model, sacrofol-7-O-glucoside significantly reduced cell apoptosis rate, restored cell vitality, and alleviated cellular damage caused by oxidative stress. In the rat focal cerebral ischemia (MCAO) model, satrin sulfol-7-O-glucoside significantly improved neurological deficits by reducing oxidative damage to brain tissue and alleviating neuroinflammatory responses, demonstrating good neuroprotective efficacy.
Acetifol-7-O-glucoside exerts anti-inflammatory effects by regulating the expression of various inflammatory factors. It has certain regulatory effects on allergic rhinitis targets such as HRH1, IL4, IL5, IL13, and FCER1A, which can alleviate allergic reactions and reduce inflammatory symptoms. Additionally, in chronic inflammatory conditions such as diabetic nephropathy, sacrofenol-7-O-glucoside reduces kidney inflammation and fibrosis by inhibiting signaling pathways such as TNF and NF-κB.
Studies have shown that in Parkinson's and Alzheimer's disease models, sacrofenol-7-O-glucoside activates the Nrf2 pathway, regulates the expression of oxidative stress-related enzymes such as GPX1 and SOD1/2, alleviates neuronal damage, and inhibits abnormal accumulation of α-synuclein (SNCA) and β-amyloid protein (APP), offering potential neuroprotective and disease-modifying effects.
The main mechanism of action of sacrosol-7-O-glucoside focuses on activation of the Nrf2/ARE signaling pathway. As a key intracellular antioxidant transcription factor, Nrf2 can induce the expression of various antioxidant and detoxifying enzyme genes after its nuclear localization is enhanced, such as superoxide dismutase (SOD1/2), glutathione peroxidase (GPX1), and vascular endothelial growth factor (VEGFA), thereby enhancing the cell's resistance to oxidative damage.
Additionally, sacrophenol-7-O-glucoside can regulate inflammation-related signaling pathways, including NF-κB and TNF-α, inhibit the release of inflammatory mediators, and reduce inflammatory responses. Its regulation of angiogenesis factors (such as VEGFA) and platelet-derived growth factor (PDGFB) helps promote the repair and regeneration of ischemic tissue.
In neurodegenerative diseases, sacrofol-7-O-glucoside slows neuronal degeneration and dysfunction by regulating mitochondrial functions (such as NDUFS1 complex I), ubiquitin-proteasome system (UBC), and dopamine receptor (DRD2).
Chlorpophenol-7-O-glucoside has a moderate molecular weight, high polarity, and good water solubility, but its low LogP value suggests weak lipid solubility, which may affect oral absorption and blood-brain barrier penetration. Its blood-brain barrier penetration ability is assessed as low, limiting its direct effect in the central nervous system and requiring improvement through drug carrier systems or structural modification.
In terms of safety, trichlorphenol-7-O-glucoside showed no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames test was negative, indicating good safety potential. Its high TPSA and hydrogen bond receptor counts suggest that it may exhibit strong protein binding and metabolic stability in vivo.
Currently, systematic studies on its pharmacokinetics are limited. Preliminary data indicate that its oral bioavailability is limited, and its metabolic pathway mainly relies on hepatic enzyme systems, with metabolites still needing further identification. In the future, research on its in vivo metabolic dynamics should be strengthened, and the design of administration routes and dosage forms should be optimized.
As a natural Nrf2 activator, sacrophilol-7-O-glucoside shows broad application prospects in various oxidative stress-related diseases. Its neuroprotective effect in ischemic stroke models offers new ideas for stroke treatment, especially in the regulation of oxidative damage and inflammatory responses in the late stage of acute ischemia.
In neurodegenerative diseases such as Parkinson's and Alzheimer's, sacrofol-7-O-glucoside regulates oxidative stress, protein misfolding, and inflammatory responses through multiple targets, potentially slowing disease progression and improving neurological function, warranting further preclinical and clinical research.
Additionally, its activity in immune regulation and anti-inflammatory makes it a potential therapeutic candidate for chronic inflammatory diseases such as allergic rhinitis and diabetic nephropathy.
Future research should focus on the following aspects: (1) In-depth analysis of its molecular mechanisms and interactions with other signaling pathways; (2) Optimize its pharmacokinetic properties to improve bioavailability and intracranial distribution; (3) Conduct systematic toxicological evaluations and preclinical safety studies; (4) Explore combination drug strategies to maximize synergistic effects; (5) Promote clinical trials to verify efficacy and safety.
Acetifol-7-O-glucoside is a natural flavonoid glycoside with significant antioxidant and neuroprotective effects. Thanks to its ability to activate the Nrf2/ARE signaling pathway, it shows broad application potential in ischemic stroke, neurodegenerative diseases, and immuno-inflammatory diseases. Its excellent safety profile and multi-target regulatory characteristics provide a solid foundation for its drug development. However, current research on its pharmacokinetics and clinical applications is still in its early stages, urgently requiring systematic in-depth research and clinical validation. In the future, with the application of new technologies and advances research, sacrofol-7-O-glucoside is expected to become an important drug candidate molecule in the field of natural product pharmacology, bringing new breakthroughs in the treatment of related diseases.
